Skip to content
stoqly

Sonoma Pharmaceuticals, Inc.

SNOA Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2017–FY2026

Revenue Total sales reported in the income statement.
$19.5M
36.7% vs prior year
Operating margin Operating income as a share of revenue.
−12.6%
13.4 pts
Net income Profit after all expenses, interest and tax.
−$3.2M
Free cash flow Cash from operations minus capital spending.
−$4.1M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
−211.8%
Market cap Last close times the latest diluted share count, so it is approximate.
—
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On −$1.22 EPS (TTM)

What Sonoma Pharmaceuticals, Inc. does

No business description yet.

Legal name
Sonoma Pharmaceuticals, Inc.
Fiscal year ends
March 31, 2026
Latest annual report
10-K · Jun 16, 2026
Accession · CIK
0001683168-26-004871
0001367083

Revenue and margins

Sonoma Pharmaceuticals, Inc. had $19.5M of revenue in fiscal 2026, up 36.7% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was −$4.1M in fiscal 2026, −21.1% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Sonoma Pharmaceuticals, Inc. returned — to shareholders in fiscal 2026. The diluted share count rose 35.7%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Sonoma Pharmaceuticals, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments $7.4M$3.8M$3.1M$5.4M$2.4M
Debt incl. finance leases $0.0M$0.4M$0.3M$0.2M$0.2M
Debt / equity 0.0x0.1x0.1x0.0x0.1x
Current ratio 2.8x3.7x3.4x3.1x2.5x
Quick ratio 2.4x2.9x2.6x2.4x1.7x
Total assets $18.8M$16.2M$14.7M$13.7M$14.0M
Total liabilities $10.1M$8.3M$8.6M$9.3M$10.9M
Shareholders' equity $8.7M$8.0M$6.1M$4.4M$3.1M
Net debt (− = net cash) −$7.4M−$3.4M−$2.8M−$5.2M−$2.2M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Net income is positive ✓ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕
Cash from operations is positive ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕
Return on assets rose — ✕ ✕ ✓ ✕ ✕ ✕ ✕ ✓ ✓
Cash from operations exceeds net income ✕ ✓ ✓ ✕ ✓ ✓ ✕ ✓ ✓ ✕
Debt fell relative to assets — ✕ ✕ ✕ ✕ ✓ ✕ ✓ ✓ ✓
Current ratio rose — ✕ ✕ ✕ ✓ ✕ ✓ ✕ ✕ ✕
Share count didn't rise — ✓ ✕ ✕ ✕ ✓ ✕ ✓ ✕ ✕
Gross margin rose — ✕ ✓ ✕ ✕ ✕ ✓ ✓ ✓ ✕
Revenue rose relative to assets — ✓ ✓ ✕ ✓ ✕ ✓ ✓ ✓ ✓
F-score — / 33 / 93 / 91 / 93 / 93 / 93 / 95 / 95 / 93 / 9
Accruals ratio 68.5%−8.5%−0.5%8.8%−3.9%−5.0%5.7%−15.7%−23.7%5.5%
Altman Z'' −11.17−23.10−37.32−38.60−36.06−29.40−34.87−40.45−44.32−44.40

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue $12.8M $16.7M $19.0M $17.9M $18.6M $12.6M $13.3M $12.7M $14.3M $19.5M
Net interest income — — — — $0.0M −$0.0M $0.0M — — —
Gross profit $5.7M $7.3M $8.9M $8.1M $6.6M $4.0M $4.5M $4.7M $5.5M $7.4M
Research and development $1.6M $1.6M $1.5M $1.3M $0.6M $0.1M $0.2M $1.9M $1.8M $2.3M
Operating income −$13.0M −$14.2M −$11.3M −$7.4M −$3.4M −$5.9M −$4.6M −$4.7M −$3.7M −$2.5M
Interest expense $0.0M $0.0M $0.0M $0.0M $0.0M — — — — —
Pretax income −$12.9M −$14.3M −$11.3M −$3.5M −$3.9M −$5.4M −$5.2M −$5.0M −$2.9M −$3.4M
Income tax −$4.3M $0.1M $0.5M $0.0M $0.7M −$0.3M −$0.0M −$0.2M $0.6M −$0.2M
Net income $9.3M −$14.3M −$11.8M −$3.3M −$4.0M −$5.1M −$5.2M −$4.8M −$3.5M −$3.2M
Diluted EPS $2.20 −$28.49 −$12.77 −$2.24 −$1.97 −$1.92 −$1.52 −$10.63 −$2.79 −$1.89
Diluted shares 0.00B 0.00B 0.00B 0.00B 0.00B 0.00B 0.00B 0.00B 0.00B 0.00B
Cash flow
Cash from operations −$8.2M −$12.4M −$11.7M −$4.6M −$3.4M −$4.2M −$6.2M −$2.4M −$0.1M −$3.9M
Capital expenditure $0.4M $0.2M $0.1M $0.2M $0.2M $0.1M $0.3M $0.0M $0.1M $0.2M
Free cash flow −$8.6M −$12.6M −$11.8M −$4.8M −$3.6M −$4.4M −$6.4M −$2.4M −$0.2M −$4.1M
Depreciation and amortization $0.2M $0.5M $0.5M $0.3M $0.2M $0.2M $0.1M $0.2M $0.1M $0.1M
Stock-based compensation $2.1M $2.5M $1.6M $0.8M $0.4M $0.4M $0.7M $0.5M $0.2M $0.3M
Balance sheet
Cash and short-term investments $17.5M $10.1M $3.7M $3.7M $4.2M $7.4M $3.8M $3.1M $5.4M $2.4M
Total debt $0.2M $0.3M $0.3M $0.5M $1.9M $0.0M $0.4M $0.3M $0.2M $0.2M
Current assets $22.6M $16.3M $12.5M $12.3M $13.0M $16.4M $13.8M $12.5M $12.6M $12.1M
Current liabilities $3.3M $3.3M $3.6M $4.7M $4.1M $5.8M $3.7M $3.7M $4.1M $4.8M
Inventory $2.2M $2.9M $3.4M $2.2M $2.5M $2.7M $2.9M $2.7M $2.9M $3.7M
Property and equipment, net $1.2M $1.1M $0.7M $0.4M $0.4M $0.3M $0.5M $0.4M $0.2M $0.3M
Total assets $25.5M $19.2M $14.4M $14.6M $15.0M $18.8M $16.2M $14.7M $13.7M $14.0M
Total liabilities $4.0M $3.9M $4.0M $8.9M $9.6M $10.1M $8.3M $8.6M $9.3M $10.9M
Preferred stock $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Shareholders' equity $21.4M $15.3M $7.8M $5.6M $5.4M $8.7M $8.0M $6.1M $4.4M $3.1M
Margins
Gross margin 44.2% 43.9% 46.8% 45.3% 35.2% 31.6% 33.7% 37.3% 38.2% 38.0%
Operating margin −101.2% −85.2% −59.3% −41.2% −18.5% −46.6% −34.4% −36.9% −26.0% −12.6%
EBITDA margin −99.2% −82.2% −57.0% −39.5% −17.3% −45.1% −33.5% −35.5% −25.0% −11.9%
Net margin 72.3% −86.0% −62.2% −18.5% −21.2% −40.3% −38.8% −38.0% −24.2% −16.3%
FCF margin −66.8% −75.8% −62.3% −26.8% −19.1% −34.7% −48.4% −18.8% −1.2% −21.1%
Net interest share of revenue — — — — 0.0% −0.1% 0.1% — — —
Returns
Return on capital −247.5% −203.0% −201.4% −241.8% −89.4% −357.5% −78.7% −111.5% — −211.8%
Return on capital employed −58.5% −89.0% −103.7% −75.2% −31.6% −45.2% −36.5% −42.7% −38.7% −27.0%
Return on equity 43.3% −78.0% −102.2% −49.4% −71.9% −72.3% −61.8% −68.5% −65.5% −84.6%
Return on assets 36.4% −64.2% −70.1% −22.8% −26.7% −30.1% −29.4% −31.2% −24.3% −23.0%
Return on tangible equity 43.3% −93.5% −151.8% −58.8% −73.7% −58.5% −64.6% −78.8% −78.4% −102.6%
Growth
Revenue growth — 29.9% 13.9% −5.5% 3.9% −32.2% 5.1% −4.0% 12.2% 36.7%
Net income growth — −254.5% — — — — — — — —
EPS growth — −1,395.0% — — — — — — — —
Share count change — −88.1% 83.7% 59.8% 35.1% −99.9% 125,603.7% −86.6% 172.7% 35.7%
Financial health
Debt / equity 0.0x 0.0x 0.0x 0.1x 0.4x 0.0x 0.1x 0.1x 0.0x 0.1x
Interest coverage −4,324.7x −354.7x −341.2x −461.9x −287.4x — — — — —
Current ratio 6.9x 5.0x 3.5x 2.6x 3.2x 2.8x 3.7x 3.4x 3.1x 2.5x
Quick ratio 6.2x 4.1x 2.5x 2.1x 2.6x 2.4x 2.9x 2.6x 2.4x 1.7x
Capital allocation
Capex / revenue 3.1% 1.1% 0.5% 1.1% 1.0% 1.1% 2.0% 0.0% 0.6% 1.0%
Stock comp / revenue 16.7% 15.0% 8.6% 4.7% 2.0% 3.0% 5.0% 4.1% 1.6% 1.3%
Quality scores
Piotroski F-score — 3.0 3.0 1.0 3.0 3.0 3.0 5.0 5.0 3.0
Altman Z'' −11.2 −23.1 −37.3 −38.6 −36.1 −29.4 −34.9 −40.4 −44.3 −44.4
Accruals ratio 68.5% −8.5% −0.5% 8.8% −3.9% −5.0% 5.7% −15.7% −23.7% 5.5%

Source: SEC EDGAR XBRL filings (CIK 0001367083). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open